| Darcy May Lucey, ANP-C | |
|
1108 E Northern Lights Blvd, Suite C, Anchorage, AK 99508-4219 | |
| (907) 688-5408 | |
| (907) 349-3056 |
| Full Name | Darcy May Lucey |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 1108 E Northern Lights Blvd, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366571564 | NPI | - | NPPES |
| NP5168 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 918 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mat-su Midwifery Inc | 5496079394 | 9 |
News Archive
ATCC, the premier biomaterials resource and standards organization, today proudly unveiled its new brand initiative. The fresh identity is a bold and confident logotype featuring the brand promise—THE ESSENTIALS OF LIFE SCIENCE RESEARCH. GLOBALLY DELIVERED.™ The new brand promise is an accurate reflection of ATCC's multiple offerings and global distribution network. Launch of the rebrand will bring focus to ATCC's extended capabilities as a reagents and tools company in support of life science research.
Encapsula NanoSciences announces the release of two new liposome based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder release cap for consumer ease.
SRI International, an independent nonprofit research and development organization, and Collaborative Drug Discovery, provider of a web-based drug discovery software platform, announced that they have been awarded a grant to support the first year of a software development project focused on tuberculosis drug discovery efforts.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
› Verified 7 days ago
| Entity Name | Mat-su Midwifery Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275696486 PECOS PAC ID: 5496079394 Enrollment ID: O20150126000566 |
News Archive
ATCC, the premier biomaterials resource and standards organization, today proudly unveiled its new brand initiative. The fresh identity is a bold and confident logotype featuring the brand promise—THE ESSENTIALS OF LIFE SCIENCE RESEARCH. GLOBALLY DELIVERED.™ The new brand promise is an accurate reflection of ATCC's multiple offerings and global distribution network. Launch of the rebrand will bring focus to ATCC's extended capabilities as a reagents and tools company in support of life science research.
Encapsula NanoSciences announces the release of two new liposome based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder release cap for consumer ease.
SRI International, an independent nonprofit research and development organization, and Collaborative Drug Discovery, provider of a web-based drug discovery software platform, announced that they have been awarded a grant to support the first year of a software development project focused on tuberculosis drug discovery efforts.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Darcy May Lucey, ANP-C 1108 E Northern Lights Blvd, Suite C, Anchorage, AK 99508-4219 Ph: (907) 688-5408 | Darcy May Lucey, ANP-C 1108 E Northern Lights Blvd, Suite C, Anchorage, AK 99508-4219 Ph: (907) 688-5408 |
News Archive
ATCC, the premier biomaterials resource and standards organization, today proudly unveiled its new brand initiative. The fresh identity is a bold and confident logotype featuring the brand promise—THE ESSENTIALS OF LIFE SCIENCE RESEARCH. GLOBALLY DELIVERED.™ The new brand promise is an accurate reflection of ATCC's multiple offerings and global distribution network. Launch of the rebrand will bring focus to ATCC's extended capabilities as a reagents and tools company in support of life science research.
Encapsula NanoSciences announces the release of two new liposome based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder release cap for consumer ease.
SRI International, an independent nonprofit research and development organization, and Collaborative Drug Discovery, provider of a web-based drug discovery software platform, announced that they have been awarded a grant to support the first year of a software development project focused on tuberculosis drug discovery efforts.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
› Verified 7 days ago
Ms. Mary Kay Mccarty, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3925 Tudor Centre Dr, #100, Anchorage, AK 99508 Phone: 907-561-8301 Fax: 907-561-8170 | |
Mindy Lorin Schloss, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6852 Cutty Sark St, Anchorage, AK 99502 Phone: 907-243-5936 | |
Katherine L Sterner, A.N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4201 Tudor Centre Dr, Suite 320, Anchorage, AK 99508 Phone: 907-729-4955 | |
Sandra Frenier, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3340 Providence Dr, Suite 452, Anchorage, AK 99508 Phone: 907-562-2120 | |
Janet A Bloch, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3851 Piper St, U340, Anchorage, AK 99508 Phone: 907-562-0321 Fax: 907-562-2683 | |
Lois A Rockcastle, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3801 University Lake Dr Ste 205, Anchorage, AK 99508 Phone: 907-563-1600 Fax: 907-563-0100 | |
Mrs. Megan Renee Hathcoat, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1200 Airport Heights Dr Ste 200, Anchorage, AK 99508 Phone: 907-262-4278 |